TScan Therapeutics, Inc. (TCRX) Tops Q3 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. ARM
3. FIS
4. BROS
5. QCOM
6. EXPE
7. FSLY
8. CPAY
9. FICO
10. PAYC

Go back to TScan Therapeutics, Inc. (TCRX) Tops Q3 EPS by 5c

TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

November 9, 2022 7:00 AM EST

Four sites for hematologic malignancies program open and enrolling patients

Completed pre-IND meeting with the FDA for solid tumor program; virtual investor event Monday, November 14, at 5:00 PM ET to highlight clinical trial design

Ended quarter with cash and cash equivalents of $137.3 million, funding operations into 2Q24

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of... More